Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia

Table 3

Factors related to the incidence of peripheral neuropathy.

Factor	Peripheral neuropathy, N (%)
	Yes	No	Not documented
Sex
Male	141 (43.8)	40 (12.4)	3 (0.9)
Female	109 (33.8)	27 (8.4)	2 (0.6)
Treatment regimen
FOLFOX	157 (48.8)	49 (15.2)	5 (1.5)
XELOX	89 (27.6)	16 (4.9)	0 (0)
FOLFOX + avastin	1 (0.3)	0 (0)	0 (0)
Oxaliplatin alone	3 (0.9)	2 (0.6)	0 (0)
Age in range (years)
30–50	37 (14.5)	8 (2.5)	0 (0)
51–60	44 (13.7)	7 (2.2)	0 (0)
61–78	146 (45.3)	38 (11.8)	4 (1.2)
79–88	23 (7.1)	14 (4.3)	1 (0.3)
Previous chemotherapy
No	235 (72.9)	62 (19.3)	5 (1.5)
Yes	15 (4.7)	5 (15.6)	0 (0)
Cancer
Adjuvant	181 (56)	48 (14.9)	4 (1.2)
Metastatic	69 (21.4)	19 (5.9)	1 (0.3)